Ultragenyx Pharmaceutical Inc. — Q2 2014 Form 10-Q
Business context and period. The filing covers the quarter and six months ended June 30, 2014. Ultragenyx is a clinical-stage biotechnology company developing treatments for rare and ultra-rare genetic diseases. Its five clinical-stage programs were in Phase 1/2 or Phase 2; it had no approved products and generated no revenue.
Key financial metrics
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $11.2 million, versus $7.2 million in 2013 | $19.6 million, versus $12.9 million in 2013 |
| General and administrative expense | $2.4 million, versus $1.0 million in 2013 | $4.4 million, versus $2.1 million in 2013 |
| Net loss | $13.6 million, versus $8.6 million in 2013 | $27.2 million, versus $15.3 million in 2013 |
| Net loss per share attributable to common stockholders | $0.45, versus $3.32 in 2013 | $1.25, versus $6.19 in 2013 |
| Cash used in operating activities | Not separately presented | $18.9 million, versus $14.7 million in 2013 |
At June 30, cash and cash equivalents were $17.5 million and short-term investments were $135.8 million, or $153.3 million combined. Current assets were $158.2 million and current liabilities $8.9 million. Total liabilities were $9.5 million; the balance sheet reported no debt. Six-month investing cash outflow was $92.9 million, largely reflecting purchases of investments, while financing provided $121.8 million, primarily from the IPO. No profit margin is meaningful because the company had no revenue.
Material changes versus prior comparable periods
- Q2 operating expenses rose 66% to $13.7 million; six-month operating expenses rose 60% to $24.0 million, driven by increased development activity, staffing, and public-company costs.
- R&D spending increased across KRN23, triheptanoin, and SA-ER programs; rhGUS spending declined from the prior year as process-development and manufacturing activity eased.
- The January–February 2014 IPO generated approximately $121.7 million in net proceeds after offering expenses and a $4.3 million preferred-stock dividend. Preferred shares converted into common stock upon the IPO.
- Six-month other expense included a $3.3 million fair-value charge for preferred-stock warrants before they converted to common-stock warrants at the IPO. These warrants were no longer remeasured afterward.
Outlook, commentary, risks, and unusual items
- Management expected existing resources, including the subsequent July 2014 offering, to fund current operations through 2016. The July offering brought the company approximately $60.2 million in net proceeds; it also included shares sold by existing stockholders, which did not generate proceeds for the company.
- Management expected losses and R&D spending to increase as clinical programs advance. Additional capital will be needed to obtain approvals and commercialize candidates; future financing may not be available on acceptable terms.
- Clinical milestones discussed included a KRN23 pediatric Phase 2 study initiated in July 2014; anticipated 2014 interim data for rhGUS and SA-ER; and expected 2015 data from triheptanoin studies. These are forward-looking expectations, not assured outcomes.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, limited rare-disease patient populations, reliance on collaborators and single-source manufacturers, and the need for future financing. The company reported no material legal proceedings and no off-balance-sheet arrangements.
- As a subsequent event, August 2014 employment amendments provided severance and, under specified circumstances following a covered transaction, accelerated equity vesting for the CEO, CFO, and chief business officer.
Important facts for investors to verify
- Whether clinical-study enrollment, data timing, and regulatory plans progress as management anticipated.
- How quickly cash and investments are consumed relative to the stated runway through 2016, including the effect of the July offering.
- Whether increased development spending produces supportive efficacy and safety evidence, and whether manufacturing supply remains available.
- The effect of future financing, equity issuance, and potential dilution; the filing reported 31,703,990 shares outstanding as of August 6, 2014.
- Whether the company’s estimates of eligible patient populations, market opportunity, and future commercial economics prove accurate.